Skip To Main Content
Weiying Gu on Muck Rack

Weiying Gu

As seen in: Nature, Wiley Online Library, Frontiers, Frontiers in Immunology, BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Weiying

Contact Weiying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy analysis of iptacopan in a patient with thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: a case report

|
By Zixuan Zhao, Lin Guo, Jiao Ge, Wei Wu, Yanhua Yue, Yan Qiu, Feng LI, Wenxi Hua, Weiying Gu, Yan Lin
| Frontiers in Immunology
Abstract To investigate the efficacy of Iptacopan in transplantation-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), we report the case of a 43-year-old male with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR, with IDH1 and STAG2 mutations) who developed TA-TMA after allo-HSCT. The patient had an initial partial response to the C5 inhibitor eculizumab, but the disease progressed.
Open in Who Shared Issue with article?

Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia | Blood Cancer Journal

|
By Qian Wu, Weiying Gu, De-Pei Wu
| Nature Verified
To the Editor, With the introduction of differentiating agents, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the outcomes of patients with acute promyelocytic leukemia (APL) have significantly improved [1, 2]. However, there are still many early deaths, especially among those at high risk [3, 4]. In our retrospective study of 570 patients with APL, early mortality was 7.54% [5].
Open in Who Shared Issue with article?

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial - Nature Communications

|
By Ming Shi, Hongming Huang, Dan Liu, Zhiling Yan, Wei Sang, Kunming Qi, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Kailin Xu, Junnian Zheng
| Nature Verified
Abstract Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo.
Open in Who Shared Issue with article?
See all 7 articles